TAVO101 is a humanized anti-TSLP monoclonal antibody modified for extended half-life (LS mutation) in phase 2 development for atopic dermatitis (NCT06176040) and plans for development in asthma, COPD, and rhinitis. Here, TSLP is linked to asthma.